Blueprint Medicines Corporation Company Profile (NASDAQ:BPMC)

About Blueprint Medicines Corporation (NASDAQ:BPMC)

Blueprint Medicines Corporation logoBlueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease. Its drug candidate, BLU-285, targets KIT, including Exon 17 mutations, and targets PDGFRa, including the D842V mutation. These mutations activate receptor tyrosine kinases that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors (GIST), and systemic mastocytosis (SM). Its drug candidate BLU-554 targets FGFR4, a kinase that is activated in a defined subset of patients with hepatocellular carcinoma (HCC), the common type of liver cancer. It is engaged in developing BLU-667, a drug candidate that targets RET, a receptor tyrosine kinase that is activated by mutations or translocations.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Symbol: NASDAQ:BPMC
  • CUSIP: N/A
  • Web: www.blueprintmedicines.com
Capitalization:
  • Market Cap: $2.46119 billion
  • Outstanding Shares: 39,122,000
Average Prices:
  • 50 Day Moving Avg: $60.49
  • 200 Day Moving Avg: $49.20
  • 52 Week Range: $25.08 - $71.67
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -15.39
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $25.58 million
  • Price / Sales: 98.13
  • Book Value: $9.57 per share
  • Price / Book: 6.70
Profitability:
  • EBITDA: ($99,210,000.00)
  • Net Margins: -388.91%
  • Return on Equity: -45.58%
  • Return on Assets: -34.66%
Debt:
  • Debt-to-Equity Ratio: 0.01%
  • Current Ratio: 13.07%
  • Quick Ratio: 13.07%
Misc:
  • Average Volume: 373,520 shs.
  • Beta: 1.32
  • Short Ratio: 5.61
 

Frequently Asked Questions for Blueprint Medicines Corporation (NASDAQ:BPMC)

What is Blueprint Medicines Corporation's stock symbol?

Blueprint Medicines Corporation trades on the NASDAQ under the ticker symbol "BPMC."

How were Blueprint Medicines Corporation's earnings last quarter?

Blueprint Medicines Corporation (NASDAQ:BPMC) released its quarterly earnings data on Wednesday, August, 2nd. The company reported ($0.86) earnings per share for the quarter, missing the consensus estimate of ($0.75) by $0.11. The company had revenue of $5.89 million for the quarter, compared to the consensus estimate of $5.96 million. Blueprint Medicines Corporation had a negative return on equity of 45.58% and a negative net margin of 388.91%. The business's revenue was down 16.7% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.70) earnings per share. View Blueprint Medicines Corporation's Earnings History.

When will Blueprint Medicines Corporation make its next earnings announcement?

Blueprint Medicines Corporation is scheduled to release their next quarterly earnings announcement on Thursday, November, 9th 2017. View Earnings Estimates for Blueprint Medicines Corporation.

Where is Blueprint Medicines Corporation's stock going? Where will Blueprint Medicines Corporation's stock price be in 2017?

9 equities research analysts have issued 12-month price objectives for Blueprint Medicines Corporation's stock. Their predictions range from $33.19 to $90.00. On average, they expect Blueprint Medicines Corporation's stock price to reach $63.47 in the next year. View Analyst Ratings for Blueprint Medicines Corporation.

What are analysts saying about Blueprint Medicines Corporation stock?

Here are some recent quotes from research analysts about Blueprint Medicines Corporation stock:

  • 1. According to Zacks Investment Research, "Blueprint Medicines Corp is an oncology company which is engaged in developing kinase inhibitors for genomically defined cancer subsets. Blueprint Medicines Corp is based in Cambridge, MA. " (10/16/2017)
  • 2. Cowen and Company analysts commented, "Blueprint Medicines presented updated data from BLU-285’s Phase I study in resistant." (6/6/2017)
  • 3. Jefferies Group LLC analysts commented, "Utilizing its drug discovery platform, BPMC is well positioned to build a balanced pipeline of proprietary & partnered products for cancer/rare disease. Early Ph1 data suggests its two candidates (BLU-285 & BLU-554) are effective & differentiated from current limited tx options, supporting further development." (12/14/2016)

Who are some of Blueprint Medicines Corporation's key competitors?

Who are Blueprint Medicines Corporation's key executives?

Blueprint Medicines Corporation's management team includes the folowing people:

  • Daniel S. Lynch, Chairman of the Board
  • Jeffrey W. Albers, President, Chief Executive Officer, Director
  • Tracey L. Mccain, executive vice president and chief legal
  • Marion Dorsch Ph.D., Chief Scientific Officer
  • Michael Landsittel, Vice President, Finance
  • Anthony L. Boral M.D. Ph.D., Chief Medical Officer
  • Kathryn Haviland, Chief Business Officer
  • Alexis Borisy, Director
  • Lonnel Coats, Independent Director
  • George D. Demetri, Independent Director

When did Blueprint Medicines Corporation IPO?

(BPMC) raised $115 million in an IPO on Thursday, April 30th 2015. The company issued 7,200,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Cowen and Company acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

How do I buy Blueprint Medicines Corporation stock?

Shares of Blueprint Medicines Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Blueprint Medicines Corporation's stock price today?

One share of Blueprint Medicines Corporation stock can currently be purchased for approximately $64.16.


MarketBeat Community Rating for Blueprint Medicines Corporation (NASDAQ BPMC)
Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  163 (Vote Outperform)
Underperform Votes:  102 (Vote Underperform)
Total Votes:  265
MarketBeat's community ratings are surveys of what our community members think about Blueprint Medicines Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Blueprint Medicines Corporation (NASDAQ:BPMC) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 9 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $63.47 (1.08% downside)
Consensus Price Target History for Blueprint Medicines Corporation (NASDAQ:BPMC)
Price Target History for Blueprint Medicines Corporation (NASDAQ:BPMC)
Analysts' Ratings History for Blueprint Medicines Corporation (NASDAQ:BPMC)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/29/2017DA DavidsonInitiated CoverageBuy$90.00HighView Rating Details
9/29/2017BTIG ResearchInitiated CoverageBuy -> Buy$90.00HighView Rating Details
9/20/2017Goldman Sachs Group, Inc. (The)Reiterated RatingBuy$64.00 -> $79.00LowView Rating Details
9/20/2017Canaccord GenuityBoost Price TargetBuy$56.00 -> $66.00MediumView Rating Details
9/5/2017Jefferies Group LLCReiterated RatingBuy$56.00MediumView Rating Details
8/22/2017WedbushReiterated RatingOutperform$66.00HighView Rating Details
6/6/2017Cowen and CompanyReiterated RatingBuyLowView Rating Details
3/22/2017JMP SecuritiesInitiated CoverageOutperform$37.00 -> $46.00LowView Rating Details
2/15/2017Morgan StanleyInitiated CoverageOverweight$45.00N/AView Rating Details
5/27/2016Raymond James Financial, Inc.Initiated CoverageOutperform$23.00N/AView Rating Details
3/9/2016J P Morgan Chase & CoLower Price TargetMarket Outperform$54.00 -> $37.00N/AView Rating Details
(Data available from 10/17/2015 forward)

Earnings

Earnings History for Blueprint Medicines Corporation (NASDAQ:BPMC)
Earnings by Quarter for Blueprint Medicines Corporation (NASDAQ:BPMC)
Earnings History by Quarter for Blueprint Medicines Corporation (NASDAQ BPMC)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2017($0.88)N/AView Earnings Details
8/2/2017Q2 2017($0.75)($0.86)$5.96 million$5.89 millionViewListenView Earnings Details
5/3/2017Q1 2017($0.73)($0.84)$6.02 million$5.84 millionViewListenView Earnings Details
3/9/2017Q4 2016($0.76)($0.75)$6.31 million$7.69 millionViewListenView Earnings Details
11/10/2016Q316($0.77)($0.62)$6.06 million$6.16 millionViewListenView Earnings Details
8/9/2016Q216($0.73)($0.70)$4.41 million$7.07 millionViewListenView Earnings Details
5/10/2016Q116($0.70)($0.57)$3.24 million$6.90 millionViewListenView Earnings Details
3/11/2016Q415($0.53)($0.58)$2.85 million$4.64 millionViewN/AView Earnings Details
11/9/2015Q3($0.54)($0.47)$1.83 million$3.43 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Blueprint Medicines Corporation (NASDAQ:BPMC)
2017 EPS Consensus Estimate: ($3.33)
2018 EPS Consensus Estimate: ($3.79)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.72)($0.72)($0.72)
Q2 20172($0.75)($0.75)($0.75)
Q3 20172($0.92)($0.90)($0.91)
Q4 20172($0.98)($0.92)($0.95)
Q1 20181($0.83)($0.83)($0.83)
Q2 20181($0.88)($0.88)($0.88)
Q3 20181($1.03)($1.03)($1.03)
Q4 20181($1.05)($1.05)($1.05)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Blueprint Medicines Corporation (NASDAQ:BPMC)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Blueprint Medicines Corporation (NASDAQ:BPMC)
Insider Ownership Percentage: 3.40%
Institutional Ownership Percentage: 90.71%
Insider Trades by Quarter for Blueprint Medicines Corporation (NASDAQ:BPMC)
Institutional Ownership by Quarter for Blueprint Medicines Corporation (NASDAQ:BPMC)
Insider Trades by Quarter for Blueprint Medicines Corporation (NASDAQ:BPMC)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/5/2017Kate HavilandInsiderSell5,449$66.44$362,031.56View SEC Filing  
9/18/2017Daniel LynchDirectorSell2,500$60.00$150,000.00View SEC Filing  
9/18/2017Kate HavilandInsiderSell6,356$60.03$381,550.68View SEC Filing  
8/9/2017Anthony L BoralInsiderSell5,000$48.60$243,000.00View SEC Filing  
8/8/2017Jeffrey W AlbersCEOSell30,000$49.62$1,488,600.00View SEC Filing  
8/7/2017Jeffrey W AlbersCEOSell20,000$49.08$981,600.00View SEC Filing  
7/5/2017Daniel LynchDirectorSell7,500$55.06$412,950.00View SEC Filing  
7/5/2017Kate HavilandInsiderSell7,265$54.66$397,104.90View SEC Filing  
6/28/2017Daniel LynchDirectorSell32,500$50.28$1,634,100.00View SEC Filing  
6/28/2017Jeffrey W AlbersCEOSell20,000$50.47$1,009,400.00View SEC Filing  
6/28/2017Kate HavilandInsiderSell6,357$50.00$317,850.00View SEC Filing  
3/16/2017Mark J LevinMajor ShareholderSell30,000$40.88$1,226,400.00View SEC Filing  
2/7/2017Rock Ventures Ii L.P. ThirdMajor ShareholderSell1,000,000$35.28$35,280,000.00View SEC Filing  
12/19/2016Kevin P. StarrMajor ShareholderSell106,489$28.19$3,001,924.91View SEC Filing  
12/1/2016Daniel LynchDirectorSell200$30.02$6,004.00View SEC Filing  
10/13/2016Daniel LynchDirectorSell21,800$30.02$654,436.00View SEC Filing  
8/8/2016Jeffrey W AlbersCEOSell17,000$22.86$388,620.00View SEC Filing  
6/3/2016Jeffrey W AlbersCEOSell17,000$20.03$340,510.00View SEC Filing  
4/13/2016Christoph LengauerInsiderSell15,872$20.01$317,598.72View SEC Filing  
4/12/2016Christoph LengauerInsiderSell18,853$20.14$379,699.42View SEC Filing  
4/6/2016Jeffrey W AlbersCEOSell17,000$20.42$347,140.00View SEC Filing  
12/17/2015Christoph LengauerinsiderSell31,119$25.05$779,530.95View SEC Filing  
11/27/2015Fmr LlcInsiderSell287,415$21.48$6,173,674.20View SEC Filing  
11/24/2015Fmr LlcInsiderSell161,271$20.14$3,247,997.94View SEC Filing  
11/23/2015Fmr LlcInsiderSell189,572$20.15$3,819,875.80View SEC Filing  
11/19/2015Fmr LlcInsiderSell237,218$19.76$4,687,427.68View SEC Filing  
11/17/2015Fmr LlcInsiderSell27,490$20.60$566,294.00View SEC Filing  
11/3/2015Christoph LengauerinsiderSell84,998$21.05$1,789,207.90View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Blueprint Medicines Corporation (NASDAQ:BPMC)
Latest Headlines for Blueprint Medicines Corporation (NASDAQ:BPMC)
Source:
DateHeadline
americanbankingnews.com logoBlueprint Medicines Corporation (BPMC) Lifted to Hold at Zacks Investment Research
www.americanbankingnews.com - October 16 at 8:10 PM
americanbankingnews.com logoZacks: Brokerages Anticipate Blueprint Medicines Corporation (BPMC) Will Post Earnings of -$0.90 Per Share
www.americanbankingnews.com - October 16 at 12:30 PM
nasdaq.com logoCommit To Purchase Blueprint Medicines Corp At $50, Earn 15.4% Annualized Using Options
www.nasdaq.com - October 13 at 10:23 PM
nasdaq.com logoBPMC Crosses Above Average Analyst Target
www.nasdaq.com - October 11 at 6:11 PM
americanbankingnews.com logoKate Haviland Sells 5,449 Shares of Blueprint Medicines Corporation (BPMC) Stock
www.americanbankingnews.com - October 10 at 7:38 PM
americanbankingnews.com logoBlueprint Medicines Corporation (BPMC) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - October 4 at 9:16 AM
seekingalpha.com logoYour Daily Pharma Scoop: Alexion's Canada Pricing, Zogenix, RedHill, Flexion
seekingalpha.com - October 2 at 1:52 PM
americanbankingnews.com logoBlueprint Medicines Corporation (BPMC) Now Covered by DA Davidson
www.americanbankingnews.com - September 29 at 10:03 AM
americanbankingnews.com logoBlueprint Medicines Corporation (BPMC) Coverage Initiated at BTIG Research
www.americanbankingnews.com - September 29 at 9:08 AM
americanbankingnews.com logoBlueprint Medicines Corporation (BPMC) Expected to Announce Earnings of -$0.90 Per Share
www.americanbankingnews.com - September 27 at 8:22 PM
americanbankingnews.com logoBlueprint Medicines Corporation (BPMC) Price Target Increased to $66.00 by Analysts at Canaccord Genuity
www.americanbankingnews.com - September 20 at 10:52 PM
americanbankingnews.com logoBlueprint Medicines Corporation (BPMC) Director Daniel Lynch Sells 2,500 Shares
www.americanbankingnews.com - September 20 at 8:24 PM
americanbankingnews.com logoInsider Selling: Blueprint Medicines Corporation (BPMC) Insider Sells 6,356 Shares of Stock
www.americanbankingnews.com - September 20 at 7:58 PM
americanbankingnews.com logoBlueprint Medicines Corporation (BPMC) Receives Buy Rating from Goldman Sachs Group, Inc. (The)
www.americanbankingnews.com - September 20 at 2:38 PM
finance.yahoo.com logoETFs with exposure to Blueprint Medicines Corp. : September 19, 2017
finance.yahoo.com - September 19 at 9:47 PM
finance.yahoo.com logoBlueprint Medicines Corp. :BPMC-US: Earnings Analysis: Q2, 2017 By the Numbers : September 18, 2017
finance.yahoo.com - September 18 at 5:04 PM
finance.yahoo.com logoBlueprint Medicines Corp. breached its 50 day moving average in a Bearish Manner : BPMC-US : September 12, 2017
finance.yahoo.com - September 12 at 5:11 PM
americanbankingnews.com logoBlueprint Medicines Corporation (BPMC) Receives Buy Rating from Canaccord Genuity
www.americanbankingnews.com - September 11 at 9:32 PM
americanbankingnews.com logoBlueprint Medicines Corporation (BPMC) Expected to Post Quarterly Sales of $5.16 Million
www.americanbankingnews.com - September 11 at 2:58 PM
finance.yahoo.com logoBlueprint Medicines Announces New Data from Ongoing Phase 1 Clinical Trial of BLU-554 in Patients with Advanced Hepatocellular Carcinoma
finance.yahoo.com - September 10 at 4:18 PM
americanbankingnews.com logoBlueprint Medicines Corporation (BPMC) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - September 9 at 9:08 AM
americanbankingnews.com logoBlueprint Medicines Corp (BPMC) Expected to Post Earnings of -$0.90 Per Share
www.americanbankingnews.com - September 9 at 2:10 AM
finance.yahoo.com logoBlueprint Medicines to Present at Morgan Stanley 15th Annual Global Healthcare Conference
finance.yahoo.com - September 6 at 4:41 PM
finance.yahoo.com logoBlueprint Medicines Corp. breached its 50 day moving average in a Bullish Manner : BPMC-US : August 24, 2017
finance.yahoo.com - August 24 at 4:46 PM
finance.yahoo.com logoBlueprint Medicines to Present Updated Data from Ongoing Phase 1 Clinical Trial of BLU-554 in Patients with Advanced Hepatocellular Carcinoma at ESMO 2017 Congress and 11th ILCA Annual Conference
finance.yahoo.com - August 22 at 10:23 PM
finance.yahoo.com logoBlueprint Medicines Corp. – Value Analysis (NASDAQ:BPMC) : August 21, 2017
finance.yahoo.com - August 22 at 10:23 PM
americanbankingnews.com logoBlueprint Medicines Corporation (BPMC) Stock Rating Reaffirmed by Wedbush
www.americanbankingnews.com - August 22 at 7:46 AM
americanbankingnews.com logoBlueprint Medicines Corporation (BPMC) Expected to Post Earnings of -$0.90 Per Share
www.americanbankingnews.com - August 21 at 10:22 AM
americanbankingnews.com logoComparing Celldex Therapeutics (CLDX) & Blueprint Medicines Corporation (BPMC)
www.americanbankingnews.com - August 19 at 12:30 PM
americanbankingnews.com logoBlueprint Medicines Corporation (BPMC) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - August 15 at 11:57 AM
americanbankingnews.com logoBlueprint Medicines Corporation (NASDAQ:BPMC) Insider Anthony L. Boral Sells 5,000 Shares
www.americanbankingnews.com - August 11 at 8:16 PM
seekingalpha.com logoBlueprint Medicines Corporation (BPMC) Presents At Canaccord Genuity 37th Annual Growth Conference - Slideshow
seekingalpha.com - August 11 at 5:07 PM
finance.yahoo.com logoFeatured Company News - Galena Biopharma Announces Merger Agreement with SELLAS Life Sciences Group
finance.yahoo.com - August 10 at 5:51 PM
finance.yahoo.com logoSee what the IHS Markit Score report has to say about Blueprint Medicines Corp.
finance.yahoo.com - August 10 at 5:51 PM
finance.yahoo.com logoBlueprint Medicines Corp. breached its 50 day moving average in a Bearish Manner : BPMC-US : August 10, 2017
finance.yahoo.com - August 10 at 5:51 PM
americanbankingnews.com logoBlueprint Medicines Corporation (NASDAQ:BPMC) CEO Jeffrey W. Albers Sells 20,000 Shares
www.americanbankingnews.com - August 9 at 7:52 PM
americanbankingnews.com logoInsider Selling: Blueprint Medicines Corporation (NASDAQ:BPMC) CEO Sells 30,000 Shares of Stock
www.americanbankingnews.com - August 9 at 7:52 PM
americanbankingnews.com logoWedbush Analysts Lower Earnings Estimates for Blueprint Medicines Corporation (NASDAQ:BPMC)
www.americanbankingnews.com - August 7 at 8:08 AM
americanbankingnews.com logoBlueprint Medicines Corporation Expected to Earn Q3 2017 Earnings of ($0.92) Per Share (NASDAQ:BPMC)
www.americanbankingnews.com - August 4 at 8:30 AM
finance.yahoo.com logoBlueprint Medicines to Present at Upcoming Investor Conferences in August
finance.yahoo.com - August 3 at 6:09 PM
finance.yahoo.com logoEdited Transcript of BPMC earnings conference call or presentation 2-Aug-17 12:30pm GMT
finance.yahoo.com - August 2 at 10:27 PM
americanbankingnews.com logoBlueprint Medicines Corporation (BPMC) Given a $56.00 Price Target at Canaccord Genuity
www.americanbankingnews.com - August 2 at 6:28 PM
finance.yahoo.com logoBlueprint Medicines Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 2 at 5:25 PM
finance.yahoo.com logoBlueprint Medicines reports 2Q loss
finance.yahoo.com - August 2 at 5:25 PM
americanbankingnews.com logoBlueprint Medicines Corporation (NASDAQ:BPMC) Releases Earnings Results, Misses Expectations By $0.11 EPS
www.americanbankingnews.com - August 2 at 1:26 PM
nasdaq.com logoStrange: Bullish BPMC Analysts Actually See -3.37% Downside
www.nasdaq.com - July 28 at 11:12 PM
finance.yahoo.com logoBlueprint Medicines to Evaluate Opportunities to Advance Rare Disease Discovery Program in Fibrodysplasia Ossificans Progressiva Following Discontinuation of Collaboration with Alexion
finance.yahoo.com - July 27 at 5:12 PM
americanbankingnews.com logoBlueprint Medicines Corporation (BPMC) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - July 27 at 10:07 AM
finance.yahoo.com logoBlueprint Medicines to Report Second Quarter 2017 Financial Results on Wednesday, August 2, 2017
finance.yahoo.com - July 26 at 5:18 PM
americanbankingnews.com logoBlueprint Medicines Corporation (BPMC) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - July 21 at 8:54 AM

Social

Chart

Blueprint Medicines Corporation (BPMC) Chart for Tuesday, October, 17, 2017

This page was last updated on 10/17/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.